Oxcia AB is a research and product development company based in Stockholm, specializing in the management of cell health and DNA repair. The company is engaged in the development of innovative products, notably OXC-101 and OXC-201, which are aimed at addressing specific medical needs. Oxcia AB collaborates with various organizations, including LEO Pharma, to enhance its research capabilities and expand its impact in the field of medical dermatology.
In addition to its product development efforts, Oxcia AB actively participates in health awareness initiatives, such as those focused on idiopathic pulmonary fibrosis (IPF) and blood cancer. The company publishes interim financial reports to maintain transparency with its stakeholders and regularly provides updates through news and press releases. Through its commitment to scientific innovation, Oxcia AB aims to improve the quality of life for patients by advancing research in dermatological health.